Medindia»Health Tips»
FDA Approved Alzheimer's Drug to Reduce Metabolic Syndrome Markers
FDA Approved Alzheimer's Drug to Reduce Metabolic Syndrome Markers
Alzheimer's medication can reduce inflammation and insulin resistance in patients with metabolic syndrome, according to a clinical trial by scientists at Northwell Health's Feinstein Institute for Medical Research. The findings could be a potential therapeutic intervention for metabolic syndrome, which affects 30 percent of the adults in the United States.